Together, Ovid Therapeutics and NeuroPointDX will use metabolomics data to better understand the rare neuro-genetic disorder known as Angelman Syndrome. NeuroPointDX’s metabolomics technology will be used in Ovid’s Phase 2 STARS trial of its drug candidate, OV101.
